Case number 1:21-cv-01107
Novartis Pharmaceuticals Corporation et al v. Lotus Pharmaceutical Co., Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Dec 13, 2023 | 121 | REDACTED VERSION of (98 in 1:21-cv-01106-MN) Answering Brief in Opposition, (117 in 1:21-cv-01107-MN) Answering Brief in Opposition, by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.. (Taylor, Daniel) (Entered: 12/13/2023) (16) |
| Dec 13, 2023 | 122 | REDACTED VERSION of (99 in 1:21-cv-01106-MN) Declaration, (118 in 1:21-cv-01107-MN) by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. (Attachments: # 1 Exhibit A)(Taylor, Daniel) Modified on 12/13/2023 (dlw). (Entered: 12/13/2023) (0) |
| Dec 13, 2023 | 123 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulation of Dismissal)(mdb) (Entered: 12/13/2023) (0) |
| Dec 12, 2023 | 119 | STIPULATION of Dismissal (as to Lotus Pharmaceutical Co., Ltd.) by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/12/2023 (dlw). (Entered: 12/12/2023) (3) |
| Dec 12, 2023 | 120 | SO ORDERED re 119 Stipulation and Order of Dismissal. Party Lotus Pharmaceutical Co., Ltd. terminated. Attorney Dominick T. Gattuso; Denise Seastone Kraft; Jeremy Lowe; James W. Sanner; Steven H. Sklar; Ashlee B. Szelag; Gregory C. Bays and Keelin D. Bielski terminated. Signed by Judge Maryellen Noreika on 12/12/2023. (dlw) (Entered: 12/12/2023) (3) |
| Dec 7, 2023 | 117 | [SEALED] ANSWERING BRIEF in Opposition re 104 MOTION to Exclude Opinion Testimony from Defendants' Putative Expert Dr. Mohamad Khasawneh filed by Lotus Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 12/14/2023. (Attachments: # 1 Certificate of Service)(Gattuso, Dominick) (Entered: 12/07/2023) (0) |
| Dec 7, 2023 | 118 | [SEALED] DECLARATION re 117 Answering Brief in Opposition, Declaration of Joanna Garelick Goldstein, Esq. by Lotus Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A)(Gattuso, Dominick) (Entered: 12/07/2023) (0) |
| Dec 1, 2023 | 112 | REDACTED VERSION of (82 in 1:21-cv-01105-MN) Opening Brief in Support, (105 in 1:21-cv-01107-MN) Opening Brief in Support, (88 in 1:21-cv-01106-MN) Opening Brief in Support, by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (16) |
| Dec 1, 2023 | 113 | REDACTED VERSION of (83 in 1:21-cv-01105-MN, 89 in 1:21-cv-01106-MN, 106 in 1:21-cv-01107-MN) Declaration, by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (30) |
| Dec 1, 2023 | 114 | CONSENT JUDGMENT AND ORDER OF INJUNCTION (re 111 ). Party Teva Pharmaceuticals Development, Inc. terminated. Signed by Judge Maryellen Noreika on 12/1/2023. (mdb) (Entered: 12/01/2023) (4) |
| Dec 1, 2023 | 115 | REDACTED VERSION of (107 in 1:21-cv-01107-MN) Joint Claim Construction Brief, (90 in 1:21-cv-01106-MN) Joint Claim Construction Brief, (84 in 1:21-cv-01105-MN) Joint Claim Construction Brief by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (30) |
| Dec 1, 2023 | 116 | REDACTED VERSION of (108 in 1:21-cv-01107-MN, 85 in 1:21-cv-01105-MN, 91 in 1:21-cv-01106-MN) Appendix, by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Pt.2 of 2)(Joyce, Alexandra) (Entered: 12/01/2023) (0) |
| Nov 30, 2023 | 111 | PROPOSED CONSENT JUDGMENT and Order of Injunction as to Defendant Teva Pharmaceutical Development, Inc. by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 11/30/2023 (mdb). (Entered: 11/30/2023) (4) |
| Nov 27, 2023 | 110 | STIPULATION TO EXTEND TIME regarding the deadline to submit redacted public versions of the Joint Claim Construction Brief (D.I. 84 in C.A. No. 21-1105, D.I. 90 in C.A. No. 21-1106, and D.I. 107 in C.A. No. 21-1107) and Joint Appendix (D.I. 85 in C.A. No. 21-1105, D.I. 91 in C.A. No. 21-1106, and D.I. 108 in C.A. No. 21-1107) to December 1, 2023 - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/27/2023) (4) |
| Nov 22, 2023 | 109 | STIPULATION TO EXTEND TIME for Briefing Schedule regarding Plaintiffs' Daubert Motion to Exclude Opinion Testimony from Defendants' Putative Expert Dr. Mohamad Khasawneh to See Stip for Details - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/22/2023) (4) |
| Nov 17, 2023 | 107 | [SEALED] JOINT CLAIM CONSTRUCTION BRIEF filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 108 | [SEALED] Joint APPENDIX re (107 in 1:21-cv-01107-MN) Joint Claim Construction Brief, (90 in 1:21-cv-01106-MN) Joint Claim Construction Brief, (84 in 1:21-cv-01105-MN) Joint Claim Construction Brief by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1-12, # 2 Exhibit 13-24, # 3 Exhibit 25-36)(Joyce, Alexandra) (Entered: 11/17/2023) (0) |
| Nov 16, 2023 | 103 | ORAL ORDER - IT IS HEREBY ORDERED that the parties shall engage in in-person mediation in good faith. The parties are to jointly hire an agreed-upon mediator. The timing of mediation efforts is left to the discretion of the parties, but the mediation must be conducted in advance of the pretrial conference. No later than one week before the pretrial conference, the parties shall submit a joint statement that identifies the mediator, the lead counsel for each party at the mediation and the length of the mediation, as well as a certification by the lead counsel that they have engaged in the mediation efforts in good faith. The joint statement should not disclose the substance of any offers, counteroffers or other negotiations. If the parties anticipate any further mediation efforts will be conducted after the deadline to submit the joint statement, the parties shall indicate that in their submission and state when those efforts are expected to occur. ORDERED by Judge Maryellen Noreika on 11/16/2023. (dlw) (Entered: 11/16/2023) (0) |
| Nov 16, 2023 | 104 | MOTION to Exclude Opinion Testimony from Defendants' Putative Expert Dr. Mohamad Khasawneh - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Counsel Pursuant to Local Rule 7.1.1.)(Joyce, Alexandra) Modified on 11/16/2023 (mdb). (Entered: 11/16/2023) (0) |
| Nov 16, 2023 | 105 | [SEALED] OPENING BRIEF in Support re 104 MOTION to Exclude Opinion Testimony from Defendants' Putative Expert Dr. Mohamad Khasawneh filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 11/30/2023. (Attachments: # 1 Certificate of Service)(Joyce, Alexandra) Modified on 11/16/2023 (mdb). (Entered: 11/16/2023) (0) |
| Nov 16, 2023 | 106 | [SEALED] DECLARATION of Robert W. Trenchard re (82 in 1:21-cv-01105-MN) Opening Brief in Support, (105 in 1:21-cv-01107-MN) Opening Brief in Support, (88 in 1:21-cv-01106-MN) Opening Brief in Support by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1-6, # 2 Certificate of Service)(Joyce, Alexandra) Modified on 11/20/2023 (dlw). (Entered: 11/16/2023) (0) |
| Nov 15, 2023 | 101 | NOTICE OF SERVICE of Defendants' First Set of Requests for Admission (Nos. 1-33) filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) (Entered: 11/15/2023) (2) |
| Nov 15, 2023 | 102 | NOTICE OF SERVICE of Joint Defendants' Highly Confidential Sur-Reply Claim Construction Brief with Exhibits filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Taylor, Daniel) (Entered: 11/15/2023) (2) |
| Nov 9, 2023 | 100 | NOTICE OF SERVICE of Plaintiffs' Reply Claim Construction Brief filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/09/2023) (5) |
| Nov 3, 2023 | 99 | NOTICE OF SERVICE of Joint Defendants' Highly Confidential Answering Claim Construction Brief with Exhibits filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Taylor, Daniel) (Entered: 11/03/2023) (2) |
| Oct 27, 2023 | 98 | NOTICE OF SERVICE of Plaintiffs' Opening Claim Construction Brief and Exhibits filed by Novartis Pharmaceuticals Corporation, Dana-Farber Cancer Institute, Inc..(Joyce, Alexandra) (Entered: 10/27/2023) (5) |
| Oct 24, 2023 | 97 | MOTION for Pro Hac Vice Appearance of Attorney Ashlee B. Szelag of Leydig, Voit & Mayer, Ltd. - filed by Lotus Pharmaceutical Co., Ltd.. (Gattuso, Dominick) (Entered: 10/24/2023) (4) |
| Oct 17, 2023 | 95 | ORAL ORDER re (94 in 1:21-cv-01107-MN, 79 in 1:21-cv-01106-MN, 73 in 1:21-cv-01105-MN) Letter - Having reviewed the parties' October 16, 2023 letter, IT IS HEREBY ORDERED that the parties may file claim construction briefing. The briefing shall follow the Court's typical briefing format (i.e., not the simultaneous briefing proposed) and the joint brief (of no more than 40 pages total (i.e., 20 pages for each side)) shall be filed no later than November 17, 2023. The Court will not set a hearing at this time. The parties should address both sides' proposed constructions with respect to positions of infringement, noninfringement, validity and invalidity in their expert reports and the pretrial order and should be prepared to do so at trial if required. ORDERED by Judge Maryellen Noreika on 10/17/2023. (dlw) (Entered: 10/17/2023) (0) |
| Oct 17, 2023 | 96 | NOTICE of Appearance by Denise Seastone Kraft on behalf of Lotus Pharmaceutical Co., Ltd. (Kraft, Denise) (Entered: 10/17/2023) (1) |
| Oct 16, 2023 | 94 | Joint Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding proposal for resolving claim construction disputes that arose during expert discovery. (Silver, Daniel) (Entered: 10/16/2023) (2) |
| Oct 2, 2023 | 92 | NOTICE OF SERVICE of (1) Sur-Reply Expert Report of Donald Small, M.D., Ph.D. on the Validity of U.S. Patent No. 7,973,031, (2) Sur-Reply Expert Report of William J. Jusko, Ph.D., and (3) Reply Expert Report of Christopher A. Vellturo, Ph.D. filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/02/2023) (5) |
| Oct 2, 2023 | 93 | NOTICE OF SERVICE of the Sur-Reply Expert Report of Mohamad K. Khasawneh, M.D., on Non-Infringement of U.S. Patent No. 8,575,146 (on behalf of the Lotus, Lupin, and Teva defendants) filed by Lupin Inc..(Lennon, James) (Entered: 10/02/2023) (2) |
| Sep 27, 2023 | 91 | NOTICE OF SERVICE of (1) Reply Expert Report of David P. Rotella, Ph.D., on the Invalidity of U.S. Patent Nos. 7,973,031 and 8,575,146; (2) Reply Expert Report of Mohamad K. Khasawneh on the Invalidity of U.S. Patent Nos. 7,973,031 and 8,575,146; (3) Reply Expert Report of S. Craig Dyar, Ph.D., R.PH; (4) Reply Expert Report of Frederick H. Hausheer, M.D., F.A.C.P.; and (5) Reply Expert Report of Ivan T. Hofmann filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Taylor, Daniel) (Entered: 09/27/2023) (2) |
| Sep 25, 2023 | 90 | NOTICE OF SERVICE of Reply Report of Mark J. Levis, M.D., Ph.D. Regarding Infringement of U.S. Patent No. 8,575,146 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/25/2023) (4) |
| Aug 22, 2023 | 89 | NOTICE OF SERVICE of Rebuttal Expert Report of Mohamad K. Khasawneh, M.D., Regarding Non-Infringement of U.S. Patent No. 8,575,145 (on behalf of the Lotus, Lupin, and Teva defendants) filed by Lupin Inc..(Lennon, James) (Entered: 08/22/2023) (2) |
| Aug 21, 2023 | 88 | NOTICE OF SERVICE of (1) First Expert Report of Donald Small, M.D., Ph.D. on the Validity of U.S. Patent No. 7,973,031, (2) Expert Report of Mark J. Levis, M.D., Ph.D. on the Validity of U.S. Patent No. 8,575,146, (3) First Expert Report of William J. Jusko, Ph.D., and (4) Expert Report of Christopher A. Vellturo, Ph.D. filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/21/2023) (5) |
| Jul 25, 2023 | 87 | STIPULATION TO EXTEND TIME See Stip for Details to - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 07/25/2023) (4) |
| Jun 5, 2023 | 85 | NOTICE OF SERVICE of (1) First Expert Report of Dr. Stephen R. Byrn, and (2) First Expert Report of Dr. Mark J. Levis filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/05/2023) (5) |
| Jun 5, 2023 | 86 | NOTICE OF SERVICE of 1. Opening Expert Report of David P. Rotella, Ph.D., on the Invalidity of U.S. Patent Nos. 7,973,031 and 8,575,146 2. Opening Expert Report of Mohamad K. Khasawneh, M.D., regarding the Invalidity of U.S. Patent Nos. 7, 973,031 and 8,575,146 3. Opening Expert Report of S. Craig Dyar, Ph.D., R.PH 4. Expert Report of Frederick H. Hausheer, M.D. FACP filed by Teva Pharmaceuticals Development, Inc..(Keller, Karen) (Entered: 06/05/2023) (2) |
| May 9, 2023 | 84 | SO ORDERED re (83 in 1:21-cv-01107-MN, 72 in 1:21-cv-01106-MN, 62 in 1:21-cv-01105-MN) Stipulation and Order Regarding Expert Discovery (Set/Reset Scheduling Order Deadlines - Opening Expert Reports due by 6/2/2023. Rebuttal Expert Reports due by 8/4/2023. Reply Expert Reports due by 9/8/2023. Sur-Reply Expert Reports due by 9/22/2023). Signed by Judge Maryellen Noreika on 5/9/2023. (dlw) (Entered: 05/09/2023) (3) |
| May 8, 2023 | 83 | STIPULATION and [Proposed] Order Regarding Expert Discovery by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 05/08/2023) (3) |
| Mar 28, 2023 | 82 | NOTICE OF SERVICE of Defendant Lotus Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) (Entered: 03/28/2023) (2) |
| Mar 17, 2023 | 81 | NOTICE requesting Clerk to remove Katherine M. Tassmer as co-counsel.. (Hoeschen, Nathan) (Entered: 03/17/2023) (1) |
| Feb 6, 2023 | 80 | STIPULATION TO EXTEND TIME for all fact discovery to be completed to April 19, 2023 - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/06/2023) (4) |
| Jan 19, 2023 | 78 | NOTICE to Take Deposition of Lotus Pharmaceutical Co., Ltd. on January 24, 2023 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/19/2023) (7) |
| Jan 19, 2023 | 79 | NOTICE to Take Deposition of Teva Pharmaceuticals Development, Inc. on February 3, 2023 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/19/2023) (7) |
| Jan 9, 2023 | 74 | NOTICE to Take Deposition of Bernard Domnic on January 25, 2023 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/09/2023) (2) |
| Jan 9, 2023 | 75 | NOTICE to Take Deposition of Danielle Kornitzer on February 9, 2023 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/09/2023) (2) |
| Jan 9, 2023 | 76 | NOTICE to Take Deposition of Jyoti Sachdeva on February 10, 2023 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/09/2023) (2) |
| Jan 9, 2023 | 77 | NOTICE to Take Deposition of Tunie Zaku on January 31, 2023 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/09/2023) (2) |
| Jan 5, 2023 | 73 | NOTICE OF SERVICE of 1. Defendants' Notice of Deposition to James Griffin 2. Defendants' Notice of Deposition to Paul Manley 3. Defendants' Notice of Deposition to Richard Stone 4. Defendants' Notice of Deposition to Ellen Weisberg 5. Defendants' Notice of Deposition to Renaud Capdeville filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) (Entered: 01/05/2023) (3) |
| Dec 20, 2022 | 72 | NOTICE OF SERVICE of Defendant Teva Pharmaceuticals Development, Inc.'s Responses to Plaintiffs' Final Infringement Contentions filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) (Entered: 12/20/2022) (2) |
| Dec 19, 2022 | 70 | NOTICE OF SERVICE of (i) Defendant Lotus Pharmaceutical Co., Ltd.'s Final Non-Infringement Contentions [HIGHLY CONFIDENTIAL]; (ii) Defendant Lotus Pharmaceutical Co., Ltd.'s Final Non-Infringement Claim Chart for U.S. Patent No. 8,575,146 [HIGHY CONFIDENTIAL]; and, (iii) Defendant Lotus Pharmaceutical Co., Ltd.'s Final Non-Infringement Claim Chart for U.S. Patent No. 7,973,031 [HIGHLY CONFIDENTIAL] filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) (Entered: 12/19/2022) (2) |
| Dec 19, 2022 | 71 | NOTICE OF SERVICE of Plaintiffs' Responses to Defendants' Final Invalidity Contentions Regarding U.S. Patent Nos. 7,973,031 and 8,575,146 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/19/2022) (5) |
| Dec 12, 2022 | 69 | NOTICE OF SERVICE of Defendants' Notice of Depositions of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) (Entered: 12/12/2022) (2) |
| Oct 26, 2022 | 68 | NOTICE OF SERVICE of Plaintiffs' Final Infringement Contentions filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/26/2022) (5) |
| Oct 25, 2022 | 67 | NOTICE OF SERVICE of Defendants' Final Invalidity Contentions filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) (Entered: 10/25/2022) (2) |
| Sep 21, 2022 | 65 | STIPULATION TO EXTEND TIME to file Final Contentions and to Extend Fact Discovery Deadline to various dates - filed by Accord Healthcare Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Lotus Pharmaceutical Co., Ltd., Teva Pharmaceuticals Development, Inc., Lupin Inc.. (Hoeschen, Nathan) (Entered: 09/21/2022) (4) |
| Sep 21, 2022 | 66 | SO ORDERED re (48 in 1:21-cv-01105-MN, 26 in 1:22-cv-00744-MN, 53 in 1:21-cv-01106-MN, 65 in 1:21-cv-01107-MN) STIPULATION TO EXTEND TIME to file Final Contentions and to Extend Fact Discovery Deadline to various dates (Set/Reset Scheduling Order Deadlines: Fact Discovery completed by 2/10/2023. Claim Construction Scheduling Order Deadlines TERMINATED). Signed by Judge Maryellen Noreika on 9/21/2022. (dlw) (Entered: 09/21/2022) (4) |
| Aug 22, 2022 | 64 | SO ORDERED re (46 in 1:21-cv-01105-MN, 51 in 1:21-cv-01106-MN, 20 in 1:22-cv-00744-MN, 63 in 1:21-cv-01107-MN) Stipulation and Order Regarding Case Coordination. Signed by Judge Maryellen Noreika on 8/22/2022. (dlw) (Entered: 08/22/2022) (6) |
| Aug 19, 2022 | 63 | STIPULATION and [Proposed] Order Regarding Case Coordination by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 08/19/2022) (6) |
| Aug 8, 2022 | 62 | NOTICE OF SERVICE of Plaintiffs' Identification on Proposed Claim Terms and Constructions filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/08/2022) (5) |
| Aug 3, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re (44 in 1:21-cv-01105-MN, 61 in 1:21-cv-01107-MN, 49 in 1:21-cv-01106-MN) Joint STIPULATION TO EXTEND TIME to substantially complete document production to August 23, 2022. ORDERED by Judge Maryellen Noreika on 8/3/2022. (dlw) |
| Aug 3, 2022 | 61 | Stipulation to EXTEND Time (3) Docket Text: Joint STIPULATION TO EXTEND TIME to substantially complete document production to August 23, 2022 - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.. (Ormerod, Eve) |
| Jul 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re (48 in 1:21-cv-01106-MN, 60 in 1:21-cv-01107-MN, 43 in 1:21-cv-01105-MN) Joint STIPULATION TO EXTEND TIME 1) for the parties to exchange a list of claim term(s)/phrase(s) needing construction and proposed constructions and 2) to exchange proposed constructions for terms proposed by another party to August 5, 2022 and August 19, 2022, respectively. ORDERED by Judge Maryellen Noreika on 7/29/2022. (dlw) |
| Jul 29, 2022 | 60 | Stipulation to EXTEND Time (3) Docket Text: Joint STIPULATION TO EXTEND TIME 1) for the parties to exchange a list of claim term(s)/phrase(s) needing construction and proposed constructions and 2) to exchange proposed constructions for terms proposed by another party to August 5, 2022 and August 19, 2022 respectively - filed by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Jul 27, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb) |
| Jul 15, 2022 | 59 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Plaintiffs' Responses to Defendants Invalidity Contentions Regarding U.S. Patent Nos. 7,973,031 and 8,575,146 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 7, 2022 | 58 | Stipulation (3) Docket Text: STIPULATION and Proposed Order to Extend Time for Plaintiffs to Serve Responses to Defendants' Invalidity Contentions to July 15, 2022 by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2022 (dlw). |
| Jun 7, 2022 | 57 | Scheduling Order (14) Docket Text: SCHEDULING ORDER: Joinder of Parties due by 12/9/2022. Amended Pleadings due by 12/9/2022. Fact Discovery completed by 12/9/2022. Opening Expert Reports due by 5/19/2023. Rebuttal Expert Reports due by 7/21/2023. Reply Expert Reports due by 8/25/2023. Expert Discovery due by 10/27/2023. Daubert Motions due by 11/10/2023. Claim Construction Opening Brief served by 12/16/2022. Claim Construction Answering Brief served by 1/20/2023. Claim Construction Reply Brief served by 2/10/2023. Claim Construction Surreply Brief served by 2/22/2023. Joint Claim Construction Brief filed by 3/3/2023. A Markman Hearing is set for 3/24/2023 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 1/19/2024 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 1/29/2024 at 08:30 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 6/7/2022. (dlw) |
| May 31, 2022 | 56 | Proposed Order (15) Docket Text: PROPOSED ORDER // Scheduling Order by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/2/2022 (dlw). |
| May 18, 2022 | 54 | ANDA Form (2) Docket Text: Amended Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 14, 2021. Date of Expiration of Patent: See Chart for Details. Statutory Stay Deadline: October 28, 2024. (Silver, Daniel) Modified on 5/18/2022 (dlw). |
| May 18, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER - Having reviewed the Amended Supplemental Information for Patent Cases Involving an Abbreviated New Drug Application (ANDA) forms wherein the stay deadline has been updated to reflect the regulatory stay deadline (10/28/2024), IT IS HEREBY ORDERED that the bench trial in these matters will be held on 1/29/2024. The parties shall submit the revised proposed scheduling order (see the Court's 4/18/2022 Oral Order) on or before 6/1/2022. ORDERED by Judge Maryellen Noreika on 5/18/2022. (dlw) |
| May 9, 2022 | 52 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Lotus Pharmaceutical Co., Ltd.'s Preliminary Non-Infringement Contentions [CONFIDENTIAL] filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
| May 9, 2022 | 53 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Teva Pharmaceuticals Development, Inc.'s Responses to Plaintiffs' Preliminary Infringement Contentions filed by Teva Pharmaceuticals Development, Inc..(Keller, Karen) |
| May 3, 2022 | 51 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Invalidity Contentions and accompanying Invalidity Claim Charts filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) |
| May 2, 2022 | 50 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Teva Pharmaceuticals Development, Inc.'s Objections and Responses to Plaintiffs' First Set of Common Requests for the Production of Documents and Things to All Defendants (Nos. 1-29) (2) Defendant Teva Pharmaceuticals Development, Inc.'s Objections and Responses to Plaintiffs' First Set of Common Interrogatories to All Defendants (Nos. 1-6) filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) |
| Apr 29, 2022 | 49 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (i) Defendant Lotus Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-6); and, (ii) Defendant Lotus Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-29) filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
| Apr 18, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER re (28 in 1:21-cv-01107-MN, 18 in 1:21-cv-01106-MN, 17 in 1:21-cv-01105-MN) Scheduling Order - IT IS HEREBY ORDERED that the parties shall conform the existing Scheduling Order in these cases to this Court's form. The bench trial will be held the week of 5/15/2023. The parties shall also provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiff serves its opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms). If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 4/18/2022. (dlw) |
| Apr 18, 2022 | 48 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of (1) Plaintiff Novartis Pharmaceuticals Corporation Responses to Defendants' First Set of Requests for Production (Nos. 1-73); (2) Plaintiff Dana-Farber Cancer Institute, Inc.'s Responses to Defendants' First Set of Requests for Production (Nos. 1-73); and (3) Plaintiffs' First Amended Paragraph 3 Disclosures filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 8, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Robert W. Trenchard for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Apr 6, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Emil N. Nachman for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 6, 2022 | 45 | Stipulation of Dismissal (2) Docket Text: STIPULATION of Dismissal of Claims Against Defendant Lotus Regarding U.S. Patent No. 8,222,244 Pursuant to Rule 41(a)(1)(A)(iii) Without Prejudice by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 4/14/2022 (dlw). |
| Apr 6, 2022 | 46 | Letter (2) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Status Report. (Silver, Daniel) |
| Apr 5, 2022 | 44 | Stipulation (3) Docket Text: Joint STIPULATION to Extend Various dates re (28 in 1:21-cv-01107-LPS) Scheduling Order,, by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Mar 31, 2022 | 43 | Stipulation to EXTEND Time (3) Docket Text: Joint STIPULATION TO EXTEND TIME to file a Joint Status Report to April 6, 2022 - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.. (Ormerod, Eve) |
| Mar 30, 2022 | 42 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' First Set of Common Interrogatories to All Defendants (Nos. 1-6) & (2) Plaintiffs' First Set of Common Requests for the Production of Documents and Things to All Defendants (Nos. 1-29) filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (27 in 1:21-cv-01106-LPS, 25 in 1:21-cv-01105-LPS, 37 in 1:21-cv-01107-LPS) PROTECTIVE ORDER; (38 in 1:21-cv-01107-LPS, 26 in 1:21-cv-01105-LPS, 28 in 1:21-cv-01106-LPS) ORDER for Discovery, Including Discovery of Electronically Stored Information ("ESI"). Signed by Judge Leonard P. Stark on 3/29/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (27 in 1:21-cv-01105-LPS, 39 in 1:21-cv-01107-LPS, 29 in 1:21-cv-01106-LPS) MOTION for Pro Hac Vice Appearance of Attorney Emil N. Nachman filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 3/29/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Mar 29, 2022 | 40 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Lotus Pharmaceutical Co., Ltd.'s Supplemental production relating to its ANDA filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 24, 2022 | 39 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Emil N. Nachman - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Emil N. Nachman)(Joyce, Alexandra) |
| Mar 24, 2022 | 39 | Certification for Emil N. Nachman (1) |
| Mar 18, 2022 | 37 | Proposed Order (27) Docket Text: PROPOSED ORDER Protective Order by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 18, 2022 | 38 | Proposed Order (11) Docket Text: PROPOSED ORDER for Discovery, Including Discovery of Electronically Stored Information ("ESI") by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Mar 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (25 in 1:21-cv-01106-LPS, 23 in 1:21-cv-01105-LPS, 36 in 1:21-cv-01107-LPS) STIPULATION TO EXTEND TIME (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 18, 2022 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 3/11/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Mar 11, 2022 | 36 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 18, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 7, 2022 | 35 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Plaintiffs' Preliminary Infringement Contentions for Defendants filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 1, 2022 | 34 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of 1. Defendants' First Set of Requests to Dana-Farber Cancer Institute, Inc. for the Production of Documents and Things (Nos. 1-73) 2. Defendants' First Set of Requests to Novartis Pharmaceuticals Corp. for the Production of Documents and Things (Nos. 1-73) filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) |
| Feb 25, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (21 in 1:21-cv-01105-LPS, 33 in 1:21-cv-01107-LPS, 22 in 1:21-cv-01106-LPS) STIPULATION TO EXTEND TIME the deadline for the parties to submit (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 11, 2022 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/25/2022. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(etg) |
| Feb 24, 2022 | 33 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME the deadline for the parties to submit (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 11, 2022 - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Feb 16, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (19 in 1:21-cv-01105-LPS, 31 in 1:21-cv-01107-LPS, 20 in 1:21-cv-01106-LPS) MOTION for Pro Hac Vice Appearance of Attorney Robert W. Trenchard filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/16/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Feb 15, 2022 | 31 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Robert W. Trenchard - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Robert W. Trenchard)(Silver, Daniel) |
| Feb 15, 2022 | 31 | Certification for Robert W. Trenchard (1) |
| Feb 15, 2022 | 32 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Kyanna Sabanoglu as co-counsel.. (Silver, Daniel) |
| Feb 11, 2022 | 30 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Notice of Service of Lotus Pharmaceutical Co., Ltd.'s Supplemental ANDA production filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
| Feb 9, 2022 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(Taylor, Daniel) |
| Feb 9, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: If during the history of this case, Plaintiff(s) and Defendant(s) jointly wish to schedule a form of alternative dispute resolution ("ADR"), such as mediation, with Judge Burke, they should contact chambers by e-mail at Deborah_Benyo@ded.uscourts.gov or by phone. Additionally, if either side wishes to speak ex parte with Judge Burke regarding ADR matters, they may contact chambers via e-mail or by phone to arrange a time for a call. Ordered by Judge Christopher J. Burke on 2/9/2020. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(dlb) |
| Feb 8, 2022 | 28 | Scheduling Order (17) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 12/16/2022. Status Report due by 9/2/2022. Joint Claim Construction Brief due by 11/9/2022. A Markman Hearing is set for 11/28/2022 at 02:00 PM before Judge Leonard P. Stark. Proposed Pretrial Order due by 8/4/2023. A Final Pretrial Conference is set for 8/11/2023 at 01:00 PM before Judge Leonard P. Stark. A 5-day Bench Trial is set for 8/21/2023 at 08:30 AM before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 2/8/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Feb 4, 2022 | 27 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Lotus Pharmaceutical Co., Ltd.'s ANDA (VOL 001) [HIGHLY CONFIDENTIAL-OUTSIDE COUNSEL ONLY] filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
| Jan 19, 2022 | 26 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); (2) Plaintiffs' Paragraph 3 Disclosures; and (3) Plaintiffs' Initial Disclosures of Accused Products and Asserted Patents filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 18, 2022 | 25 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Teva Pharmaceuticals Development, Inc.'s Initial Disclosures (2) Teva Pharmaceuticals Development, Inc.'s Paragraph 3 Discovery Disclosures filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) |
| Jan 14, 2022 | 24 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Initial Disclosures of Lotus Pharmaceutical Co., Ltd. Pursuant to Fed. R. Civ. P. 26(a)(1) and Paragraph 3 of the Default Standard for Discovery filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
| Jan 6, 2022 | 22 | Proposed Order (19) Docket Text: PROPOSED ORDER Scheduling by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 6, 2022 | 23 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Stipulated Proposed Scheduling Order - re (22 in 1:21-cv-01107-LPS, 13 in 1:21-cv-01105-LPS, 13 in 1:21-cv-01106-LPS) Proposed Order. (Silver, Daniel) |
| Dec 27, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [21] STIPULATION TO EXTEND TIME to Submit a Proposed Scheduling Order to January 6, 2022 filed by Teva Pharmaceuticals Development, Inc. Signed by Judge Leonard P. Stark on 12/27/21. (ntl) |
| Dec 22, 2021 | 21 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to Submit a Proposed Scheduling Order to January 6, 2022 - filed by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Dec 14, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [20] STIPULATION TO EXTEND TIME [and Proposed Order] to submit a joint proposed scheduling order to December 23, 2021 filed by Teva Pharmaceuticals Development, Inc. Signed by Judge Leonard P. Stark on 12/13/21. (ntl) |
| Dec 10, 2021 | 20 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME [and Proposed Order] to submit a joint proposed scheduling order to December 23, 2021 - filed by Teva Pharmaceuticals Development, Inc.. (Keller, Karen) |
| Dec 2, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposal, including a proposal for the length and timing of trial, to the Court no later than December 16, 2021. The parties are to review the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Stark, New Patent Procedures). ORDERED by Judge Leonard P. Stark on 12/2/21. (ntl) |
| Oct 12, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Steven H. Sklar for Lotus Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Oct 7, 2021 | 18 | Answer to Counterclaim (12) Docket Text: ANSWER to [15] Answer to Complaint, Counterclaim by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Sep 24, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [17] MOTION for Pro Hac Vice Appearance of Attorney Steven M. Coyle, Nicholas A. Geiger, and Katherine M. Tassmer filed by Teva Pharmaceuticals Development, Inc. Signed by Judge Leonard P. Stark on 9/24/21. (ntl) |
| Sep 24, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Nicholas A. Geiger,Katherine M. Tassmer,Steven M. Coyle for Teva Pharmaceuticals Development, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Sep 24, 2021 | 17 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Steven M. Coyle, Nicholas A. Geiger, and Katherine M. Tassmer - filed by Teva Pharmaceuticals Development, Inc.. (Keller, Karen) |
| Sep 17, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Kyanna Sabanoglu, Anne Y. Brody, Ronald A. Lee, Sung Bin Lee for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(srs) |
| Sep 17, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jane M. Love for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(srs) |
| Sep 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (14 in 1:21-cv-01107-LPS, 11 in 1:21-cv-01105-LPS, 12 in 1:21-cv-01106-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 9/16/21. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Sep 16, 2021 | 15 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM and Affirmative Defenses against All Plaintiffs by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) |
| Sep 16, 2021 | 16 | Disclosure Statement (4) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd., Other Affiliate Teva Holdco US, Inc for Teva Pharmaceuticals Development, Inc. filed by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Sep 15, 2021 | 14 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee)(Silver, Daniel) |
| Sep 15, 2021 | 14 | Certifications for Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, (5) |
| Aug 25, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Gregory C. Bays for Lotus Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Aug 23, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [13] MOTION for Pro Hac Vice Appearance of Attorney Jeremy Lowe, Steven H. Sklar, Gregory C. Bays, James W. Sanner, and Keelin D. Bielski of Leydig, Voit & Mayer, Ltd. filed by Lotus Pharmaceutical Co., Ltd. Signed by Judge Leonard P. Stark on 8/23/21. (ntl) |
| Aug 23, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney James W. Sanner,Jeremy Lowe for Lotus Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Aug 23, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Keelin D. Bielski for Lotus Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Aug 20, 2021 | 11 | Answer to Complaint (9) Docket Text: ANSWER to [1] Complaint, Answer and Affirmative Defenses By Defendant Lotus Pharmaceutical Co., Ltd. by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
| Aug 20, 2021 | 12 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Alvogen Emerging Markets Holding Limited, Corporate Parent Alvogen Lux Holdings S..r.l., Corporate Parent Innobic (Asia) Company Limited, Corporate Parent PTT Public Company Limited, Corporate Parent The Ministry of Finance of Thailand for Lotus Pharmaceutical Co., Ltd. filed by Lotus Pharmaceutical Co., Ltd.. (Gattuso, Dominick) |
| Aug 20, 2021 | 13 | Motion for Leave to Appear Pro Hac Vice (8) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jeremy Lowe, Steven H. Sklar, Gregory C. Bays, James W. Sanner, and Keelin D. Bielski of Leydig, Voit & Mayer, Ltd. - filed by Lotus Pharmaceutical Co., Ltd.. (Gattuso, Dominick) |
| Aug 9, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [10] STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to September 20, 2021 filed by Teva Pharmaceuticals Development, Inc. Signed by Judge Leonard P. Stark on 8/9/21. (ntl) |
| Aug 5, 2021 | 10 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to September 20, 2021 - filed by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Aug 4, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (rjb) |
| Jul 30, 2021 | 1 | Main Document (16) Docket Text: COMPLAINT filed against Lotus Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Development, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3668345.) - filed by Novartis Pharmaceuticals Corporation and Dana-Farber Cancer Institute, Inc.. (Attachments: # (1) Exhibit A-C, # (2) Civil Cover Sheet)(srs) |
| Jul 30, 2021 | 1 | Exhibit A-C (70) |
| Jul 30, 2021 | 1 | Civil Cover Sheet (3) |
| Jul 30, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Jul 30, 2021 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 14, 2021. Date of Expiration of Patents: July 13, 2025, October 29 2022, and December 2, 2030.Thirty Month Stay Deadline: 12/14/2023. (srs) |
| Jul 30, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,973,031 ;8,222,244 ;8,575,146. (srs) |
| Jul 30, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (srs) |
| Jul 30, 2021 | 6 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Dana-Farber Cancer Institute, Inc.. (srs) |
| Jul 30, 2021 | 7 | Summons Issued (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Lotus Pharmaceutical Co., Ltd. on 7/30/2021. (srs) |
| Jul 30, 2021 | 8 | Summons Issued (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Teva Pharmaceuticals Development, Inc. on 7/30/2021. (srs) |
| Jul 30, 2021 | 9 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation, Dana-Farber Cancer Institute, Inc.. Teva Pharmaceuticals Development, Inc. served on 7/30/2021, answer due 8/20/2021. (Joyce, Alexandra) |
| Jul 30, 2021 | 1 | Complaint* (1) |
